Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments

July 11, 2017, Johns Hopkins University School of Medicine
Healthy skin biopsy. Credit: Michael Polydefkis

Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression. With a quicker and less invasive way to visualize the hallmark protein clumps of the rare but lethal disease—familial transthyretin amyloidosis—the researchers say they hope to more rapidly advance clinical trials of treatments that may slow the disease and extend patients' lives.

In a report on their study, published June 20 as an Early View article online in Annals of Neurology, the Johns Hopkins team found that increasing levels of the protein clumps corresponded with worsening , indicating that the smaller skin biopsies they used appear to work well as a measure of severity.

People with the transthyretin amyloidosis have mutations in the DNA of the transthyretin gene, which causes abnormal buildup and deposits of a transport protein called transthyretin in nerve and heart cells. Patients typically experience progressive pain, muscle weakness and ultimately kidney, heart and other organ failure, with the disease usually manifesting itself in people ages 40 to 60. Although precise estimates of the disease's prevalence are unknown, the disorder is rare, striking about 1 in 100,000 Americans of European descent; the rates are thought to be higher in African Americans.

"In the last few months, we've diagnosed several people with the disease years before the diagnosis is typically made, which has changed how we do medicine in our nerve clinic," says Michael Polydefkis, M.D., professor of neurology at the Johns Hopkins University School of Medicine and senior author on the study.

Polydefkis, also director of the Cutaneous Nerve Lab at the Johns Hopkins Bayview Medical Center, says that with transthyretin amyloidosis typically have traditional symptoms of nerve damage, known as neuropathy, such as numbness or burning in the feet. But unlike typical neuropathy patients, transthyretin amyloidosis patients develop more rapid progression of their disease as well as additional symptoms, such as problems with their digestion and irregular heartbeat, within about three to five years.

Traditionally, a firm diagnosis of the disorder requires a surgical nerve biopsy followed by genetic tests. From initial onset of symptoms, patients on average live about 10 to 12 years.

Over the past few years, Polydefkis and his team have developed a skin biopsy he uses to diagnose other types of nonfatal neuropathies by measuring the number of nerve fibers in the skin samples taken from the leg. The skin biopsy takes a small, 3 mm-wide sample of tissue (about half the width of a pencil eraser) and can be performed in a doctor's office.

The new study was designed to see if a faster and better diagnosis could be made for transthyretin amyloidosis using a modified version of the skin biopsy technique.

For the study, his group recruited 30 patients with six different genetically-confirmed transthyretin amyloidosis mutations. Twenty patients had neuropathy symptoms and 10 did not. They also recruited 20 age and gender-matched healthy controls, and 20 age and gender-matched patients with diabetic neuropathy—a different form of peripheral nerve damage due to high blood sugar. Participants ranged in age from 17 to 83; 42 percent were women.

Skin biopsy from a patient with amyloidosis. Protein clumps are in red. Credit: Michael Polydefkis

Each subject had skin biopsies taken from their outer ankle and upper thigh. The biopsies were thinly sliced and stained with a dye called Congo red that allowed the researchers to view the protein clumps in the layers of skin or within the sweat glands and pilomotor muscles (those that cause goose bumps) under the microscope. These red protein clumps looked yellowish-green when observed with a polarized lens distinguishing them from other structures in the skin sample.

Researchers observed the protein clumps in 14 people with symptoms of neuropathy and the disease and in two people with the disease but without accompanying neuropathy symptoms. The protein clumps weren't seen in any of the healthy controls or in samples from people with diabetic neuropathy.

Based on their results, Gigi Ebenezer, M.B.B.S., M.D., assistant professor of neurology and the first author on the study, reported that protein clumps were detected in 70 percent of cases and 20 percent of patients who carried disease-causing genes but hadn't yet developed symptoms. None of the control cases showed amyloid.

The researchers also examined skin slices from two patients with another form of nerve disease called AL amyloidosis, caused by a bone marrow disorder. They also could see red protein clumps in the skin samples of these people, sparing them a more invasive nerve biopsy.

Next, the researchers compared the quantity of protein clumps compared to the level of disability in the lower legs of each participant. The quantity of protein clumps was calculated using a computer program that measured the amount of tissue in a skin slice with protein clumps expressed as a percentage of the tissue's total area. The disability score ranged from 0 (no disability) to 88 (severely disabled) and incorporated measurements of sensation, muscle power, tendon reflexes and electrical activity in the leg nerves.

The average disability score in healthy participants was 0.2. In patients with transthyretin amyloidosis but no symptoms, the average score was 4.4 and in patients with the disease and neuropathy symptoms the average score was 31.8. Healthy controls had an average of 0 percent protein clumps in their skin samples, while those with transthyretin amyloidosis but no symptoms had an average of 0.4 percent protein clumps and symptomatic patients with the disease had an average of 26.3 percent protein clumps. Higher percentages of protein clumping corresponded to greater disability in people with transthyretin amyloidosis.

"The disability level aligned with the quantity of amyloid ( clumps) present makes intuitive sense, but we were really amazed that the information from a small skin biopsy would correlate so well with disease severity," says Polydefkis. "It suggests that what we find in the skin reflects what the disease is doing in the rest of the body."

He cautions that his group only tested the six most common transthyretin mutations and that hundreds of other mutations exist in the gene that may not show similar patterns.

"But if further studies confirm and extend what we have found, we may use the biopsy as a biomarker for disease severity. And we will be able to diagnose more patients sooner, which is important for patients and their families so they can begin planning for the future," says Polydefkis. "The good news is that drug companies are using our technique in ongoing clinical trials to monitor treatment success." He says results from phase II and III trials on these new therapies designed to stall the disease are slated to come out within the year.

The incidence of transthyretin amyloidosis worldwide is unknown, according to the U.S. National Library of Medicine. People of African descent may have rates as high as 3-5 percent.

Explore further: Researchers use RNAi to silence genes that cause transthyretin amyloidosis

More information: Gigi J. Ebenezer et al. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy, Annals of Neurology (2017). DOI: 10.1002/ana.24972

Related Stories

Researchers use RNAi to silence genes that cause transthyretin amyloidosis

August 29, 2013
(Medical Xpress)—An international team of researchers has discovered a way to silence the genes that cause transthyretin amyloidosis—a fatal genetic disease. In their paper published in the New England Journal of Medicine, ...

Office-based test developed to identify amyloidosis-related heart failure

February 8, 2017
Boston researchers have developed a new diagnostic test that may help doctors identify patients with a condition called cardiac amyloidosis. The findings appear in the journal JAMA Cardiology.

Small nerve fibers defy neuropathy conventions

April 11, 2016
Results of a small study of people with tingling pain in their hands and feet have added to evidence that so-called prediabetes is more damaging to motor nerves than once believed, in a report on the study published online ...

Amyloid-related heart failure now detectable with imaging test

August 24, 2016
A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study led by researchers at Columbia ...

Improved chances of discovering hereditary transthyretin amyloidosis

January 26, 2016
New insights in hereditary transthyretin amyloidosis (ATTR) improve the chances of diagnosing the genetic disease using ECG and ultrasound. In a new doctoral dissertation by Sandra Arvidsson at Umeå University in Sweden, ...

To fix diabetic nerve damage, blood vessels and support cells may be the real targets of treatment

June 23, 2011
Blood vessels and supporting cells appear to be pivotal partners in repairing nerves ravaged by diabetic neuropathy, and nurturing their partnership with nerve cells might make the difference between success and failure in ...

Recommended for you

Broken shuttle may interfere with learning in major brain disorders

June 22, 2018
Unable to carry signals based on sights and sounds to the genes that record memories, a broken shuttle protein may hinder learning in patients with intellectual disability, schizophrenia, and autism.

Scientists discover fundamental rule of brain plasticity

June 21, 2018
Our brains are famously flexible, or "plastic," because neurons can do new things by forging new or stronger connections with other neurons. But if some connections strengthen, neuroscientists have reasoned, neurons must ...

Scientists discover how brain signals travel to drive language performance

June 21, 2018
Effective verbal communication depends on one's ability to retrieve and select the appropriate words to convey an intended meaning. For many, this process is instinctive, but for someone who has suffered a stroke or another ...

Researchers find mechanism behind choosing alcohol over healthy rewards

June 21, 2018
A new study links molecular changes in the brain to behaviours that are central in addiction, such as choosing a drug over alternative rewards. The researchers have developed a method in which rats learn to get an alcohol ...

Waking up is hard to do: Prefrontal cortex implicated in consciousness

June 21, 2018
Philosophers have pondered the nature of consciousness for thousands of years. In the 21st century, the debate over how the brain gives rise to our everyday experience continues to puzzle scientists. To help, researchers ...

Study on instinctive behaviour elucidates a synaptic mechanism for computing escape decisions

June 21, 2018
How does your brain decide what to do in a threatening situation? A new paper published in Nature describes a mechanism by which the brain classifies the level of a threat and decides when to escape.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.